Introduction
============

There are \>1,000 species of bacteria in the intestinal tract, known as intestinal microbiota. The genomes of these species encode \>100-fold unique genes compared to the human genome ([@b1-mmr-09-06-2205]). The intestinal microbiota is dominated by five bacterial phyla (Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia) and one Archaea (Euryarchaeota) ([@b2-mmr-09-06-2205]). These complex communities of microorganisms play an important role in metabolic, nutritional, physiological and immunological processes in the human body ([@b3-mmr-09-06-2205]). Molecular characterization of the intestinal microbiota by phylogenetic approaches has received considerable attention in recent years and revealed a remarkable compositional stability and resilience in adult life, even after pervasive treatments with antibiotics ([@b4-mmr-09-06-2205]). Species of the genera *Bifidobacterium* and *Lactobacillus* are particularly present in the colon of healthy individuals, and they are generally regarded as desirable, owing to the reduction of the neutral pH to a more acidic pH that they cause ([@b5-mmr-09-06-2205]). Changes in microbial community composition are closely associated with various diseases, such as allergic disease ([@b6-mmr-09-06-2205]), colorectal cancer ([@b7-mmr-09-06-2205]) and intestinal inflammatory disease ([@b8-mmr-09-06-2205]).

Our understanding of intestinal microbiota and their importance for the human physiology has increased, owing to international research initiatives such as the MetaHIT project ([@b1-mmr-09-06-2205]) and the Human Microbiome Project ([@b9-mmr-09-06-2205]). However, the development of simple protocols for the manipulation of intestinal microbiota in experimental animal models is still needed. Recently, a study focusing on the effects of intestinal microbiota depletion on the gut mucosa and epithelial gene expression was performed; depletion of the intestinal microbiota was achieved in mice by administering broad-spectrum antibiotics in drinking water ([@b10-mmr-09-06-2205]). The study reported that antibiotic treatment significantly reduced the expression of antimicrobial factors to a level similar to that of germ-free mice, and altered the expression of a total of 517 genes in the colonic epithelium. The expression of genes involved in the cell cycle was significantly altered, concomitant with reduced epithelial proliferative activity *in situ*, as assessed by Ki-67 expression, which suggested that commensal microbiota drives cellular proliferation in the colonic epithelium ([@b10-mmr-09-06-2205]). Metabolites produced by the gut microbiota community from processes such as oxidation reduction and lipid metabolism have been reported to considerably affect intestinal functions ([@b1-mmr-09-06-2205]).

The present study used a previously released microarray dataset ([@b10-mmr-09-06-2205]) to assess the effects of intestinal microbiota depletion in mice, by focusing on the gene expression profiles of colonic intestinal epithelial cells in the presence and absence of intestinal microbiota. These profiles were analyzed using a series of bioinformatic methods, including protein-protein interaction (PPI) network construction, module functional annotation and pathway enrichment analyses. Further research on the mechanisms identified here as affected by the intestinal microbiota depletion is planned for a future study.

Materials and methods
=====================

Affymetrix microarray analysis
------------------------------

The raw data and the probe annotation files from the gene expression profiling dataset GSE22648 (10; accession no. GDS3921) were downloaded from the Gene Expression Omnibus database (the National Center of Biotechnology Information; <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22648>). These data were obtained on a GPL6887 platform using MouseWG-6 v2.0 expression beadchips (Illumina, Inc., San Diego, CA, USA). Data from a total of 11 chips were analyzed, corresponding to colonic intestinal epithelial cell gene expression profiles of 5 replicates from mice with depleted intestinal microbiota and 6 replicates from control mice that were not treated with antibiotics (germ-free).

Identification and clustering analysis of differentially expressed genes (DEGs)
-------------------------------------------------------------------------------

The raw data were preprocessed using the Affy package in R ([@b11-mmr-09-06-2205]). Differential expression analysis between the 5 intestinal microbiota-depleted and the 6 control samples was performed using limma, a linear regression model software package available in R ([@b12-mmr-09-06-2205]), and multiple testing correction was performed using a Bayesian method ([@b13-mmr-09-06-2205]). The DEGs between intestinal microbiota-depleted and control samples were defined as these genes showing a \|log fold change (FC)\| \>1 and a false discovery rate (FDR) \<0.05. To visualize the expression profiles of DEGs and all genes, unsupervised hierarchical clustering analysis was performed ([@b14-mmr-09-06-2205]).

PPI network construction
------------------------

The search tool for the retrieval of interacting genes (STRING) ([@b15-mmr-09-06-2205]) database was used to retrieve the predicted interactions for the identified DEGs; the version 9.0 of STRING covers \>1,100 completely sequenced species. All associations available in STRING are provided with a probabilistic confidence score, which was derived by separately benchmarking groups of associations against the a manually curated functional classification scheme ([@b15-mmr-09-06-2205]). Each score represents a rough estimate of how likely a given association describes a functional linkage between two gene products. The DEGs with a confidence score \>0.8 were selected to construct the PPI network, using the open-source Cytoscape software ([@b16-mmr-09-06-2205]). Cytoscape (<http://cytoscape.org/>) allows visualizing complex networks and integrating these networks to any type of attribute data.

Functional analysis of modules from the PPI network
---------------------------------------------------

The MCODE ([@b17-mmr-09-06-2205]) plugin in Cytoscape was used to further divide the PPI into modules, using a cutoff value for the connectivity degree of nodes (proteins in the network) \>2. Gene Ontology (GO) functional annotation and enrichment analysis of genes in the resulting modules was performed using the PiNGO plugin in Cytoscape ([@b18-mmr-09-06-2205]) with a threshold P\<0.05 based on a hypergeometric test.

Pathway analysis
----------------

Information on the biological pathways in which the module-related DEGs are involved was retrieved from the Kyoto Encyclopedia of Genes and Genomes pathways database (<http://www.genome.jp/kegg/pathway.html>) ([@b19-mmr-09-06-2205],[@b20-mmr-09-06-2205]). Visualization of these pathways and enrichment analysis was performed using the GenMAPP software ([@b19-mmr-09-06-2205]). GenMAPP is a powerful tool for graphically viewing microarray data in the context of pathway analysis in an intuitive manner for biologists, and it was previously used in the analysis of microarray data related to allergic disease ([@b21-mmr-09-06-2205]). P\<0.05 was set as the threshold used for enrichment analysis of KEGG pathways.

Results
=======

Identification of DEGs
----------------------

The normalized expression values following preprocessing of the raw data are shown in [Fig. 1](#f1-mmr-09-06-2205){ref-type="fig"}. Differential expression analysis on these values using FDR\<0.05 and \|log FC\|\>1 as cutoff criteria identified a total of 53 genes differentially expressed between depleted intestinal microbiota and control mice. Among these DEGs, 26 were upregulated and 27 were downregulated upon microbiota depletion.

Clustering analysis of DEGs
---------------------------

Hierarchical clustering analysis was performed on the expression values of all genes and of the 53 DEGs. Clearly distinct expression patterns were observed between the microbiota-depleted and the control mice in both the total gene and DEG clustering analysis ([Fig. 2](#f2-mmr-09-06-2205){ref-type="fig"}).

PPI analysis and module functional annotation
---------------------------------------------

The PPI network was constructed ([Fig. 3A](#f3-mmr-09-06-2205){ref-type="fig"}) based on the predicted interactions of 14 DEGs showing a confidence score \>0.8. Using the MCODE plugin in Cytoscape, the PPI network was divided into three modules ([Fig. 3B--D](#f3-mmr-09-06-2205){ref-type="fig"}). Modules 1, 2 and 3 were found to be significantly enriched (P\<0.05) for 12, 14 and 14 Gene Ontology (GO) terms, respectively ([Table I](#tI-mmr-09-06-2205){ref-type="table"}). The two most significant GO terms in module 1 were oxidation reduction (P=1.9321E-21) and metabolic process (P=1.1226E-12). The DEGs in module 1 ([Fig. 3B](#f3-mmr-09-06-2205){ref-type="fig"}), i.e., the cytochrome P450 (CYP) 4B1 isozyme gene (*CYP4B1*), *CYP2D10* and *CYP2D26*, which were upregulated ([Table II](#tII-mmr-09-06-2205){ref-type="table"}), and *CYP2C55*, which was downregulated, were all involved in these two processes ([Table I](#tI-mmr-09-06-2205){ref-type="table"}). In addition, *CYP4B1* was found to be involved in all enriched GO term functions of module 1. The terms unsaturated fatty acid, lipid, cellular lipid and fatty acid metabolic process were the most significantly enriched functions in module 2, and the upregulated gene *CYP4F14* ([Fig. 3C](#f3-mmr-09-06-2205){ref-type="fig"}, [Table II](#tII-mmr-09-06-2205){ref-type="table"}) was predicted to be involved in all these functions ([Table I](#tI-mmr-09-06-2205){ref-type="table"}). Notably, the neuropeptide signaling pathway was the most significantly enriched function (P=2.5213E-11) in module 3, and the upregulated gene tachykinin precursor 1 (*TAC1*) ([Fig. 3D](#f3-mmr-09-06-2205){ref-type="fig"}, [Table II](#tII-mmr-09-06-2205){ref-type="table"}) was predicted to be involved in this function ([Table I](#tI-mmr-09-06-2205){ref-type="table"}). The top 5 DEGs in terms of significance ([Table II](#tII-mmr-09-06-2205){ref-type="table"}) were all upregulated upon microbiota depletion.

Pathway analysis
----------------

Pathway enrichment analysis using the GenMAPP software was performed on the list of DEGs the products of which are parts of the three PPI modules. Module 1 was found to be significantly enriched for a total of 12 pathways, module 2 for 5 and module 3 for 2 ([Table III](#tIII-mmr-09-06-2205){ref-type="table"}). The most significant pathways in module 1 included metabolism of xenobiotics by P450s (P=2.20E-26), linoleic acid metabolism (P=6.54E-24) and arachidonic acid metabolism (P=1.49E-10). Significant pathways in module 2 also included arachidonic acid metabolism (P=5.61E-10) and linoleic acid metabolism (P=3.95E-02). Two pathways were significantly enriched in module 3, the calcium signaling pathway (P=3.23E-03) and neuroactive ligand-receptor interaction (P=5.95E-03).

Discussion
==========

The collective genome of the human intestinal microbiota was estimated to contain 3.3 million microbial genes, which is \~150 times more genes than the human genome. Intestinal microbiota mostly use fermentation to generate energy, converting sugars, in part, to short-chain fatty acids, which are used by the host as an energy source ([@b1-mmr-09-06-2205]). To understand the impact of intestinal microbiota on human health, it is crucial to assess their potential function. The present study identified a total of 53 DEGs, comprising 26 upregulated and 27 downregulated genes upon depletion of the intestinal microbiota in mice. Important differences in gene expression were observed between intestinal microbiota-depleted and control mice in hierarchical clustering analysis. The PPI network of DEGs was constructed and divided into 3 modules, with the most significant module-related DEGs being *CYP4B1* in module 1, *CYP4F14* in module 2 and *TAC1* in module 3. The majority of enriched pathways of module 1 and 2 were oxidation reduction (metabolism of xenobiotics by CYPs) and lipid (e.g., linoleic and arachidonic acid) metabolism pathways. In addition, the neuropeptide signaling pathway was the most significantly enriched pathway in module 3.

Two types of functions of intestinal microbiota have been identified in a previous study, those required in all bacteria and those potentially specific to the gut ([@b1-mmr-09-06-2205]). Functions of the first category relate to central metabolic pathways (for example, carbon metabolism and amino acid synthesis) and to important protein complexes (RNA and DNA polymerase, ATP synthase, general secretory apparatus) ([@b1-mmr-09-06-2205]). The putative gut-specific functions include those involved in adhesion to host proteins (collagen, fibrinogen, fibronectin), or in harvesting sugars of the globo-series glycolipids, which are carried on blood and epithelial cells ([@b1-mmr-09-06-2205]). In the present study, most of module 1-related DEGs were involved in oxidation reduction and metabolic processes such as metabolism of xenobiotics by CYPs, and the majority of module 2-related DEGs were involved in lipid metabolic processes, such as lipid metabolic process and arachidonic acid metabolism. These results suggest that the intestinal microbiota is involved in numerous metabolic and biosynthetic processes, but has particularly important roles in the regulation of lipid biosynthesis and in oxidation-reduction processes, as also indicated by previous studies ([@b22-mmr-09-06-2205]--[@b24-mmr-09-06-2205]).

Further analysis of the most significant DEGs *CYP4B1*, *CYP2D10*, *CYP2D26* (module 1) and *CYP4F14* (module 2) revealed that *CYP4B1* and *CYP4F14* are involved in almost all of the functions of each PPI module. In rats and rabbits, the CYP4B1 protein was shown to play an important role in mutagenic activation of procarcinogens in the organs ([@b25-mmr-09-06-2205]). Most of organic xenobiotics require metabolic activation to electrophilic intermediates to produce adverse carcinogenic effects. Specific enzymes of the CYP superfamily are involved in the formation of reactive metabolites from certain substrates that are predicted or known occupational and environmental carcinogens ([@b26-mmr-09-06-2205]). A new prodrug-activating enzyme system for pharmacogenic therapy of experimental brain tumors based on the rabbit CYP4B1 protein was previously described ([@b27-mmr-09-06-2205]). CYP4Fs are a subfamily of enzymes involved in arachidonic acid metabolism and showing the highest catalytic activity towards leukotriene (LT)B4, a potent chemoattractant involved in inflammation. CYP4F-mediated metabolism of LTB4 leads to inactive ω-hydroxy products, incapable of initiating chemotaxis and the inflammatory stimuli that result in the influx of inflammatory cells ([@b28-mmr-09-06-2205]). The *CYP4B1* and *CYP4F14* genes were identified as significantly upregulated in the present study, which, in combination with previous reports, suggests that intestinal microbiota depletion may lead to inflammation and cancer in the body.

It is notable that modules 1 and 2 were both enriched for the processes of arachidonic and linoleic acid metabolism. Arachidonic acid is a polyunsaturated ω-6 fatty acid that is released in response to tissue injury. Arachidonic acid is a pivotal signaling molecule, involved in the initiation and propagation of diverse signaling cascades regulating inflammation, pain and homeostatic functions ([@b29-mmr-09-06-2205]). It is metabolized by three enzymatic pathways: the cyclooxygenase pathway produces prostanoid, the lipoxygenase pathway yields monohydroxy compounds and LTs, while the CYP epoxygenase pathway generates hydroxy and epoxyeicosanoids. There is increasing evidence that some of these metabolic products play critical roles in cardiovascular disease ([@b29-mmr-09-06-2205]). Linoleic acid is predominant in dairy products and plant oils such as flax seed, and animal studies have reported a reduction in intra-abdominal fat and an enhanced gain in fat-free mass upon linoleic acid supplementation; another study reported linoleic acid-mediated whole-body fat loss in overweight men and women; there have also been some concerns that linoleic acid can promote oxidative stress and induce hepatic lipid accumulation ([@b30-mmr-09-06-2205]--[@b32-mmr-09-06-2205]). Based on these studies and the present findings on arachidonic and linoleic acid metabolism, the two processes appear to play a key role in human health and to be closely linked to the balance of intestinal microbiota.

In contrast to the reported effects of intestinal microbiota on oxidation reduction and lipid metabolism ([@b30-mmr-09-06-2205]--[@b32-mmr-09-06-2205]), an association between intestinal microbiota and the neuropeptide signaling pathway has not been previously reported. In our study, it is notable that the neuropeptide signaling pathway was the most significantly enriched pathway in module 3. Among the here-identified DEGs, *TAC1* is predicted to be involved in this pathway. This gene encodes a neurotransmitter of the central and peripheral nervous system ([@b33-mmr-09-06-2205]), and the protein has additionally been associated with immunologic and inflammatory processes ([@b34-mmr-09-06-2205]). The gut and the brain are closely connected organs, and their interaction plays an important role not only in gastrointestinal function, but also in certain feeling states and in intuitive decision making ([@b35-mmr-09-06-2205]); alterations in this interaction have been associated with a wide range of disorders, including functional, inflammatory gastrointestinal, and eating disorders. It has been reported that healthy humans and rats produce autoantibodies directed against appetite-regulating peptide hormones and neuropeptides, suggesting that these autoantibodies may play physiological roles in hunger- and satiety-related pathways ([@b36-mmr-09-06-2205]). Gut-related antigens including those produced by the intestinal microflora, may affect the production of these autoantibodies, which might represent a new link between the gut and the regulation of appetite. We thus argue that the depletion of the intestinal microflora in mice may lead to impaired neuropeptide signaling.

In conclusion, our findings strongly suggest that intestinal microbiota depletion affects metabolism, oxidation reduction and neuropeptide signaling pathways in mice, involving a number of genes and interactions. Numerous diseases, as well as aging, can be induced by depletion of the intestinal microflora, and therefore, the dynamic equilibrium of the intestinal microflora plays a key role in human health. The neuropeptide signaling pathway was first reported in the present study to be affected by the depletion of the intestinal microflora, a result which reveals a potential link between the intestinal bacteria and the nervous system. However, further experimentation and additional studies are needed to confirm this link; such studies are expected to enhance our understanding of the interactions between the bacteria of the intestinal microflora and their host environment.
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![Clustering analysis of gene expression values of (A) all genes and (B) of differentially expressed genes. The change of color from green to red represents the change in \|log FC\| from low to high. FC, fold change.](MMR-09-06-2205-g01){#f2-mmr-09-06-2205}

![Primary protein-protein interaction (PPI) network and selected modules. (A) PPI network for products of differentially expressed genes (DEGs). (B--D) Modules including significant DEGs (confidence score \>0.8). Red- and green-color nodes represent products of up- and downregulated DEGs, respectively. Purple nodes denote products of genes predicted to interact with the DEGs.](MMR-09-06-2205-g02){#f3-mmr-09-06-2205}

###### 

Functional annotation of the genes in the three modules using Gene Ontology (GO) terms.

  A, Significantly enriched GO terms (n=12) and associated DEGs in module 1                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------- ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  55114                                                                        1.9321E-21   *CYP2J5, CYP2C70, CYP2D9, CYP2D10, CYP2C37, CYP2C55, CYP3A25, CYP2C54, CYP3A13, CYP2C44, CYP3A11, CYP2C29, CYP2C40, CYP2E1, CYP1A2, CYP4B1, CYP2D26*                                                     Oxidation reduction
  8152                                                                         1.1226E-12   *CYP2J5, CYP2C70, CYP2D9, CYP2D10, CYP2C37, CYP2C55, CYP3A25, CYP2C54, CYP3A13, CYP2C44, CYP3A11, CYP2C29, UGT2B1, CYP2C40, CYP2E1, CYP1A2, UGT1A1, UGT3A2, CYP4B1, CYP2A12, UGT2B35, UGT2B5, CYP2D26*   Metabolic process
  42537                                                                        9.6276E-10   *UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                         Benzene and derivative metabolic process
  6805                                                                         2.6493E-08   *UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                         Xenobiotic metabolic process
  71466                                                                        2.6493E-08   *UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                         Cellular response to xenobiotic stimulus
  6725                                                                         2.6493E-08   *CYP2A12, UGT2B35, UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                       Cellular aromatic compound metabolic process
  9410                                                                         3.7437E-08   *UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                         Response to xenobiotic stimulus
  70887                                                                        4.26E-04     *UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                         Cellular response to chemical stimulus
  44248                                                                        1.01E-03     *UGT2B35, UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                Cellular catabolic process
  9056                                                                         3.27E-03     *UGT2B35, UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                Catabolic process
  42221                                                                        7.25E-03     *UGT2B1, CYP2D26, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                Response to chemical stimulus
  51716                                                                        9.66E-03     *UGT2B1, CYP1A2, UGT1A1, CYP4B1*                                                                                                                                                                         Cellular response to stimulus
                                                                                                                                                                                                                                                                                                     
  B, Significantly enriched GO terms (n=14) and associated genes in module 2                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                     
  GO id                                                                        Corr. P      Genes in test set                                                                                                                                                                                        Functional description
                                                                                                                                                                                                                                                                                                     
  33559                                                                        2.0285E-08   *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Unsaturated fatty acid metabolic process
  6629                                                                         1.1496E-07   *PTGS2, PLB1, PTGS1, PLA2G2A, CYP4F14, ALOX5*                                                                                                                                                            Lipid metabolic process
  44255                                                                        1.2555E-06   *PTGS2, PTGS1, PLA2G2A, CYP4F14, ALOX5*                                                                                                                                                                  Cellular lipid metabolic process
  6631                                                                         2.1203E-06   *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Fatty acid metabolic process
  32787                                                                        9.1722E-06   *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Monocarboxylic acid metabolic process
  43436                                                                        5.05E-05     *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Oxoacid metabolic process
  19752                                                                        5.05E-05     *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Carboxylic acid metabolic process
  6082                                                                         5.05E-05     *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Organic acid metabolic process
  42180                                                                        5.26E-05     *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Cellular ketone metabolic process
  55114                                                                        8.20E-05     *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Oxidation reduction
  44281                                                                        1.02E-03     *PTGS2, PTGS1, CYP4F14, ALOX5*                                                                                                                                                                           Small molecule metabolic process
  44238                                                                        1.89E-03     *PTGS2, PLB1, PTGS1, PLA2G2A, CYP4F14, ALOX5*                                                                                                                                                            Primary metabolic process
  8152                                                                         3.03E-03     *PTGS2, PLB1, PTGS1, PLA2G2A, CYP4F14, ALOX5*                                                                                                                                                            Metabolic process
  44237                                                                        9.30E-03     *PTGS2, PTGS1, PLA2G2A, CYP4F14, ALOX5*                                                                                                                                                                  Cellular metabolic process
                                                                                                                                                                                                                                                                                                     
  C, Significantly enriched GO terms (n=14) and associated genes in module 3                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                     
  GO id                                                                        Corr. P      Genes in test set                                                                                                                                                                                        Functional description
                                                                                                                                                                                                                                                                                                     
  7218                                                                         2.5213E-11   *GRP, TACR3, TACR2, TACR1, TAC1, TAC2*                                                                                                                                                                   Neuropeptide signaling pathway
  8015                                                                         1.8064E-10   *NTS, TACR3, TACR1, AGT, TAC1, TAC2*                                                                                                                                                                     Blood circulation
  3013                                                                         1.8064E-10   *NTS, TACR3, TACR1, AGT, TAC1, TAC2*                                                                                                                                                                     Circulatory system process
  7186                                                                         1.1712E-07   *GRP, TACR3, TACR2, TACR1, AGT, TAC1, GAST, TAC2*                                                                                                                                                        G-protein coupled receptor protein signaling pathway
  7166                                                                         8.8661E-07   *GRP, TACR3, TACR2, TACR1, AGT, TAC1, GAST, TAC2*                                                                                                                                                        Cell surface receptor linked signaling pathway
  23033                                                                        4.6021E-06   *GRP, TACR3, TACR2, TACR1, AGT, TAC1, GAST, TAC2*                                                                                                                                                        Signaling pathway
  51239                                                                        4.8121E-06   *GRP, TACR3, TACR2, TACR1, AGT, TAC1*                                                                                                                                                                    Regulation of multicellular organismal process
  3008                                                                         4.9678E-06   *NTS, TACR3, TACR2, TACR1, AGT, TAC1, TAC2*                                                                                                                                                              System process
  65008                                                                        1.24E-05     *NTS, TACR3, TACR1, AGT, TAC1, TAC2*                                                                                                                                                                     Regulation of biological quality
  23052                                                                        1.33E-05     *GRP, TACR3, TACR2, TACR1, AGT, TAC1, GAST, TAC2*                                                                                                                                                        Signaling
  65007                                                                        4.55E-05     *GRP, NTS, TACR3, TACR2, TACR1, AGT, TAC1, GAST, TAC2*                                                                                                                                                   Biological regulation
  32501                                                                        4.32E-04     *NTS, TACR3, TACR2, TACR1, AGT, TAC1, TAC2*                                                                                                                                                              Multicellular organismal process
  50794                                                                        2.08E-03     *GRP, TACR3, TACR2, TACR1, AGT, TAC1, GAST*                                                                                                                                                              Regulation of cellular process
  50789                                                                        2.69E-03     *GRP, TACR3, TACR2, TACR1, AGT, TAC1, GAST*                                                                                                                                                              Regulation of biological process

Corr. P, corrected p-value; *CYP*, cytochrome P450 gene; *TAC1*, tachykinin precursor 1 gene.

###### 

Characteristics of the most significant differentially expressed genes in the 3 modules.

  Id             Gene symbol   FDR         \|log FC\|   GO terms[a](#tfn2-mmr-09-06-2205){ref-type="table-fn"}    Regulation
  -------------- ------------- ----------- ------------ --------------------------------------------------------- ------------
  ILMN_2790496   *CYP4B1*      0.0023580   2.64         All in [Table IA](#tI-mmr-09-06-2205){ref-type="table"}   Up
  ILMN_1229535   *CYP2D10*     0.0234023   1.42         55114, 8152                                               Up
  ILMN_2704777   *CYP2D26*     0.0190232   1.92         55114, 8152, 42221                                        Up
  ILMN_1231625   *CYP4F14*     0.0055720   1.31         All in [Table IB](#tI-mmr-09-06-2205){ref-type="table"}   Up
  ILMN_1251000   *TAC1*        0.0257095   1.09         All in [Table IC](#tI-mmr-09-06-2205){ref-type="table"}   Up

The numbers denote Gene Ontology (GO) ids shown in [Table I](#tI-mmr-09-06-2205){ref-type="table"}.

FC, fold change; CYP, cytochrome P450; TAC1, tachykinin precursor 1; FDR, false discovery rate.

###### 

Pathway enrichment analysis of differentially expressed genes in the three modules based on information from the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways database for *Mus musculus* (mmu).

  Module   KEGG id                                                          P
  -------- ---------------------------------------------------------------- ----------
  1        mmu00980: Metabolism of xenobiotics by cytochrome P450           2.20E-26
           mmu00830: Retinol metabolism                                     3.63E-26
           mmu00591: Linoleic acid metabolism                               6.54E-24
           mmu00983: Drug metabolism                                        1.30E-10
           mmu00590: Arachidonic acid metabolism                            1.49E-10
           mmu00140: Steroid hormone biosynthesis                           5.88E-09
           mmu00053: Ascorbate and aldarate metabolism                      1.18E-03
           mmu00040: Pentose and glucuronate interconversions               1.52E-03
           mmu00860: Porphyrin and chlorophyll metabolism                   4.74E-03
           mmu00150: Androgen and estrogen metabolism                       4.74E-03
           mmu00500: Starch and sucrose metabolism                          6.77E-03
           mmu00232: Caffeine metabolism                                    3.10E-02
  2        mmu00590: Arachidonic acid metabolism                            5.61E-10
           mmu04370: Vascular endothelial growth factor signaling pathway   1.69E-03
           mmu00592: α-linolenic acid metabolism                            1.56E-02
           mmu00565: Ether lipid metabolism                                 3.01E-02
           mmu00591: Linoleic acid metabolism                               3.95E-02
  3        mmu04020: Calcium signaling pathway                              3.23E-03
           mmu04080: Neuroactive ligand-receptor interaction                5.95E-03
